Telix Pharmaceuticals Limited’s Return on Assets at a glance
Telix Pharmaceuticals Limited reports return on assets of 3.3% for Dec 2024. The prior period recorded 1.3% (Dec 2023). Year over year the metric moved +2 pts (+151.6%). The rolling three-period average stands at -12.1%. Data last refreshed Dec 7, 2025, 2:45 AM.
Latest reading
3.3% · Dec 2024
YoY movement
+2 pts (+151.6%)
Rolling average
-12.1%
Current Return on Assets
3.3%
+2 pts
+151.6%
Rolling average
-12.1%
Latest Value
3.3%
Dec 2024
YoY Change
+2 pts
Absolute
YoY Change %
+151.6%
Rate of change
3-Period Avg
-12.1%
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s return on assets stands at 3.3% for Dec 2024. Year-over-year, the metric shifted by +2 pts, translating into a +151.6% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How return on assets shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports return on assets of 3.3%. Track return on assets to gauge balance sheet efficiency, asset intensity, and capital deployment versus peers.
Asset efficiency signal
Higher ROA indicates management is generating greater profit from the asset base. Watch for multi-year trends and industry benchmarks.
Use with leverage metrics
Compare ROA with ROE to understand how leverage magnifies returns on equity versus returns produced by total assets.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s return on assets profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current return on assets?
As of Dec 2024, Telix Pharmaceuticals Limited reports return on assets of 3.3%. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's return on assets trending year over year?
Year-over-year, the figure shifts by +2 pts (+151.6%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does return on assets matter for Telix Pharmaceuticals Limited?
Return on assets measures how efficiently a company turns average assets into net income. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's return on assets above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at -12.1%. Comparing the latest reading of 3.3% to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's return on assets refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:45 AM and updates automatically every 24 hours, keeping your valuation inputs current.